


**Our Vision:** To be the Global Leader in Testing for Life

**Our Mission:** To contribute to a safer and healthier world by providing our customers with innovative and high-quality laboratory, research and advisory services, whilst creating opportunities for our employees and generating sustainable shareholder value

**Our Values:** Customer Focus, Quality, Competence & Team Spirit and Integrity

#### Full year revenues in €million



#### Eurofins shares are listed on Euronext Paris

(since IPO at €0.18 in October 1997)

##### Tickers:

ISIN FR0014000MR3, Euronext ERF, Reuters EUFI.PA, Bloomberg ERF FP

##### Index Membership:

Euronext Paris: CAC 40, Euronext 100, SBF 120, SBF TOP 80 EW, CAC ALL SHARES, CAC ALL-TRADABLE, CAC HEALTH CARE, CAC LARGE 60, ESG B SCR WLD USD.

Euronext Amsterdam: EN CORE E100 EW, EN EUR N100 EW, EN EUROZONE 150 EW, EN EUROPE 500, EN EUROZONE 300, EN EZ L&M 60 EW, EN EZ 100 ESG.

Other: MSCI Europe, STOXX Europe 600

#### Contact details

Investor Relations  
[ir@eurofins.com](mailto:ir@eurofins.com)

Please refer to our [on-line group directory](#) for laboratory contact information and [www.eurofins.com](http://www.eurofins.com)

## FACTSHEET

### Eurofins overview

Eurofins is Testing for Life. Eurofins is the global leader in food, environment, pharmaceutical and cosmetic product testing and in agrosience Contract Research services. Eurofins is also one of the market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, BioPharma Contract Development and Manufacturing, advanced material sciences and in the support of clinical studies. The Group also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.

### History

Eurofins Scientific was founded in 1987 with four employees to market the SNIF-NMR® technology, a patented analytical method used to verify the origin and purity of several types of food and beverages and identify sophisticated fraud not detectable by other methods.

Today, the Eurofins Group is a leading provider of testing and analytical services with:

- an international network of **940 laboratories** in **59 countries**
- **Over 61,000** staff
- a portfolio of over **200,000** analytical methods
- more than **450 million** tests performed each year

On September 17<sup>th</sup>, 2021, Eurofins joined the CAC 40 index and has been for over two decades one of the fastest growing listed European companies. Since its IPO on the Paris stock exchange in 1997, Eurofins' revenues have increased by 33% each year (in compound average) to reach €6.7 billion in 2021. Furthermore, between the Initial Public Offering on 24 October 1997 (€0.183) and 30 June 2022 (€75.08), Eurofins' share price has multiplied by 410 times, an annual average increase of 28% (against 4% for the SBF 120, 3% for the CAC 40, 6% for the S&P 500 and 8% for the NASDAQ over the same period).

### A commitment to innovation and sustainability

Since its foundation, Eurofins has contributed significantly to the advancement of science through Testing for Life. We are proud of the discoveries our specialists have made in a broad range of sectors, from food to pharma or forensics testing. Our laboratories around the world are helping to improve cancer treatments, fight the growing problem of antibiotic resistance, catch criminals, safeguard the health of bees, ensure our food and water is safe, indicate paternity, protect transplant patients' lives and combat viruses like COVID-19 and monkeypox. Whether we are helping to improve health outcomes, ensure food safety or determine environmental impact, sustainability is at the heart of our work. By its nature, our work helps corporations, organisations and governments improve their environmental and societal impact. On the ground, we are working to become carbon neutral by 2025 through reduction and offsetting of carbon emissions, whilst the Eurofins Foundation is supporting charities and NGOs across the world, who share our goal to make the world a safer and healthier place for all.

### Recent developments

Even though COVID-19 testing activities have declined in H1 2022 against record comparables in 2021, the Group continues to maintain testing capacity to help combat the COVID-19 pandemic, from conducting PCR testing to supporting our BioPharma customers in the development and manufacturing of vaccines, treatments and therapies. Should a new significant wave or another more pathogenic variant arise, Eurofins stands ready to assist governments and health authorities with innovative tests and solutions. In parallel, Eurofins Viracor entered into an exclusive license agreement with Cornell University to commercialize several ground-breaking and novel assays aimed at transforming the clinical management of COVID-19 and transplant patients impacted from tissue damage and infections. Additionally, Eurofins Viracor entered an exclusive license with Stanford University to commercialize testing of certain biomarkers for the prediction of severe outcomes in patients with infections.

Furthermore, in response to the recent outbreak of the monkeypox virus, Gold Standard Diagnostics Europe, a Eurofins Technologies Company, has developed a new multiplex Real-time PCR assay for the detection of the monkeypox virus and its differentiation from other orthopox viruses. The multiplex Real-time PCR assay complements GSD Europe's suite of assays developed in response to infectious diseases, such as the GSD NovaPrime and NovaType assay families, developed for SARS-CoV-2 detection and variant identification.

Group revenues have increased to record levels in 2021 and H1 2022. Laboratories of the Group continued to make scientific advances and innovations in multiple core business areas including the world's first official method for the identification of fructans certified by the AOAC and ISO bodies, the world's first AOAC Performance Tested Methods<sup>SM</sup> status for a screening method to detect aflatoxin M1 in milk commodities, Viracor TRAC<sup>TM</sup>, a proprietary donor-derived cell-free DNA assay for detection of acute kidney rejection, TruGraf Liver, a unique, non-invasive blood-based test to support liver transplant patients and PFAS Exposure<sup>TM</sup>, the first direct to consumer at-home test to determine levels of PFAS in a person's blood and measure 47 of the PFAS "forever chemical" compounds.

### Outlook

The business outlook remains very strong in almost all our areas of activity. Eurofins' focus on Testing for Life and long-term investment to build a leading global position and unmatched state-of-the-art laboratory network has created a solid foundation for strong profitable organic growth in the future. It increasingly appears that the consequences resulting from the pandemic should drive increasing demand for Eurofins' services for many years to come and we remain confident to emerge from current challenges the world is facing, as an even more resilient, innovative and effective group of companies. Going forward, Eurofins intends to continue to invest significantly to be the most digital and innovative member of its industry and participate meaningfully in the new markets opened by the many recent genomic, proteomic, and life sciences scientific breakthroughs.